Business
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering. The shares of common stock are being sold at a public
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Nektar is selling 6,603,449 shares of common stock and 293,103 pre-funded warrants in the offering. The shares of common stock are being sold at a public offering price of $58.00 per share and the pre-funded warrants to purchase are being sold at a public offering price of $57.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds to Nektar from the offering are expected to be approximately $400 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional 1,034,482 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities being sold in this offering are being offered by Nektar. The offering is expected to close on February 13, 2026, subject to the satisfaction of customary conditions.","length":1446,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Nektar Therapeutics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Nektar Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":145,"url":"https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ls4zow06UG_HUOQnS5yvKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537","width":400,"height":145}},"href":"https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development (including Phase 3 trials for rezpegaldesleukin) and manufacturing co...